MX2020008395A - Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. - Google Patents

Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.

Info

Publication number
MX2020008395A
MX2020008395A MX2020008395A MX2020008395A MX2020008395A MX 2020008395 A MX2020008395 A MX 2020008395A MX 2020008395 A MX2020008395 A MX 2020008395A MX 2020008395 A MX2020008395 A MX 2020008395A MX 2020008395 A MX2020008395 A MX 2020008395A
Authority
MX
Mexico
Prior art keywords
treatment
osimertinib
lung cancer
small cell
cell lung
Prior art date
Application number
MX2020008395A
Other languages
English (en)
Inventor
Anthony Francis Patrick Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2020008395A publication Critical patent/MX2020008395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La memoria descriptiva se refiere a osimertinib o una sal farmacéuticamente aceptable del mismo para su uso en el tratamiento de pacientes con cáncer de pulmón de células no pequeñas con mutación positiva con receptor del factor de crecimiento epidérmico (EGFR) no resecable localmente avanzado (Estadio III)), y en particular al tratamiento de pacientes cuya enfermedad no ha progresado después de la terapia de quimiorradiación a base de platino definitiva.
MX2020008395A 2018-02-12 2019-02-11 Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas. MX2020008395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862629166P 2018-02-12 2018-02-12
PCT/EP2019/053311 WO2019155059A1 (en) 2018-02-12 2019-02-11 Osimertinib for use in the treatment of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
MX2020008395A true MX2020008395A (es) 2020-09-21

Family

ID=65443828

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008395A MX2020008395A (es) 2018-02-12 2019-02-11 Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.

Country Status (15)

Country Link
US (4) US20200368231A1 (es)
EP (2) EP3752153A1 (es)
JP (2) JP2021513517A (es)
KR (1) KR20200119243A (es)
CN (2) CN116870008A (es)
AU (2) AU2019219304A1 (es)
BR (1) BR112020015507A2 (es)
CA (1) CA3090010A1 (es)
EA (1) EA202091841A1 (es)
IL (1) IL276406A (es)
MA (1) MA51823A (es)
MX (1) MX2020008395A (es)
SG (1) SG11202007414XA (es)
TW (2) TW202412804A (es)
WO (1) WO2019155059A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110433296A (zh) * 2019-08-16 2019-11-12 哈尔滨医科大学 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用
MX2022008874A (es) * 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
WO2022120197A1 (en) * 2020-12-03 2022-06-09 Emory University Combinations of epidermal growth factor receptor inhibitors and sterol regulatory element-binding protein inhibitors for uses in cancer therapies
CN114917231A (zh) * 2022-05-27 2022-08-19 杭州师范大学 β-榄香稀和奥希替尼药物组合在制备抗肺癌药物上的应用
KR20240126585A (ko) 2023-02-14 2024-08-21 박주현 좁은 전시공간에서 전시품의 360도 실감 영상투사식 전시장치

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105348266B (zh) 2011-07-27 2018-04-10 阿斯利康(瑞典)有限公司 取代的3‑氯‑n‑[3‑(嘧啶‑2‑基氨基)苯基]丙酰胺或其盐
GB201400034D0 (en) 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
CA2959775A1 (en) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
US10813933B2 (en) * 2016-05-17 2020-10-27 Japanese Foundation For Cancer Research Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance

Also Published As

Publication number Publication date
EP4431154A2 (en) 2024-09-18
US20230226059A1 (en) 2023-07-20
CN116870008A (zh) 2023-10-13
BR112020015507A2 (pt) 2021-01-26
US20220184076A1 (en) 2022-06-16
AU2022203007B2 (en) 2024-07-04
MA51823A (fr) 2021-05-19
SG11202007414XA (en) 2020-09-29
JP2023116537A (ja) 2023-08-22
EA202091841A1 (ru) 2020-10-28
TW202412804A (zh) 2024-04-01
EP3752153A1 (en) 2020-12-23
CN111683663A (zh) 2020-09-18
WO2019155059A1 (en) 2019-08-15
AU2019219304A1 (en) 2020-09-24
TW201941773A (zh) 2019-11-01
AU2022203007A1 (en) 2022-05-26
KR20200119243A (ko) 2020-10-19
CA3090010A1 (en) 2019-08-15
JP2021513517A (ja) 2021-05-27
US20200368231A1 (en) 2020-11-26
IL276406A (en) 2020-09-30
US20240156815A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
MX2020008395A (es) Osimertinib para su uso en el tratamiento de cáncer de pulmón de células no pequeñas.
MX2020009773A (es) Terapia de combinacion.
MX2017014338A (es) Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina.
SG170730A1 (en) Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
MX2021014137A (es) Pertuzumab para usarse en el tratamiento de cancer de mama her2 positivo.
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
MX2020012799A (es) Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
PH12018502549A1 (en) Pharmaceutical combinations
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
NZ598145A (en) Folate-targeted diagnostics and treatment
NZ756264A (en) Treatment of brain cancer
MX2016011045A (es) Terapia de combinacion para cancer.
MX2024002822A (es) Composicion farmaceutica y uso de la misma.
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
MX2021003842A (es) Terapia combinada para el tratamiento del cancer.
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
WO2020243273A3 (en) Methods of treating cholangiocarcinoma
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX364523B (es) Tratamiento eficaz de nsclc y marcador clínico predictivo de la respuesta de un tumor a un tratamiento.
EA202192552A1 (ru) Осимертиниб для применения в лечении немелкоклеточного рака легкого
WO2017164887A8 (en) Pulse dosing regimen and methods for treatment
Vaubel Epidermal growth factor receptor antagonists/mitogen-activated protein kinase kinase inhibitors
BR112022003286A2 (pt) Combinação de poziotinibe com inibidores de vegfr2 e métodos de uso da mesma
Thota Visual loss, mucositis, and anasarca: 3 case reports